Memantine

Generic Name: Memantine

Brand Names: Axura, Ebixa, Marixino, Namenda, Namenda 49 Titration Pack, Namzaric, Nemdatine, Memantine Mylan, Memantine ratiopharm, Memantine Merz, Marixino (previously Maruxa), Memantine Accord, Memantine LEK

Drug Type: Small Molecule

Chemical Formula: C_₁₂H_₂₁N

CAS Number: 19982-08-2

Unique Ingredient Identifier: W8O17SJF3T

Background: Initially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD). It is different from many other Alzheimer's Disease medications, as it works by a different mechanism than the cholinesterase enzyme inhibitors normally employed in the management of Alzheimer's disease . ...

Indication: Memantine is used to manage moderate to severe Alzheimer's dementia .
...

Associated Conditions: Alzheimer's Disease (AD), Moderate to Severe Alzheimer's Disease, Mild Vascular dementia, Moderate Alzheimer's Type Dementia, Moderate Vascular dementia, Severe Alzheimer's Type Dementia

Associated Therapies: -

Clinical Trials

Memantine for the Treatment of Cognitive Dysfunction and Negative Symptoms in Patients With Chronic Schizophrenia

Phase 3

Terminated

Conditions: Chronic Schizophrenia

Interventions: Drug: Memantine
Drug: Placebos

First Posted Date: 2005-09-08

Last Posted Date: 2019-06-27

Lead Sponsor: M. Schaefer, MD

Target Recruit Count: 13

Registration Number: NCT00148616

Locations: 🇩🇪
Charité Universitaetsmedizin Berlin; Campus Charité Mitte; Dept. for Psychiatry and Psychotherapy, Berlin, Germany

Memantine for the Prevention of Cognitive Dysfunction and Negative Symptoms in Patients With Acute Schizophrenia

Phase 3

Terminated

Conditions: Schizophrenia

Interventions: Drug: Memantine
Drug: Placebo

First Posted Date: 2005-09-08

Last Posted Date: 2019-06-27

Lead Sponsor: M. Schaefer, MD

Target Recruit Count: 24

Registration Number: NCT00148590

Locations: 🇩🇪
Charité Universitaetsmedizin Berlin; Campus Charité Mitte; Dept. for Psychiatry and Psychotherapy, Berlin, Germany

Memantine in Patients With Chronic Glaucoma

Phase 3

Completed

Conditions: Open-Angle Glaucoma

First Posted Date: 2005-09-02

Last Posted Date: 2010-11-04

Lead Sponsor: Allergan

Target Recruit Count: 1119

Registration Number: NCT00141882

Effect of Memantine Versus Bupropion on Smoking Relapse in Nicotine-Dependent Individuals - 3

Phase 1

Completed

Conditions: Tobacco Use Disorder

Interventions: Drug: Memantine

First Posted Date: 2005-08-29

Last Posted Date: 2018-05-21

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 25

Registration Number: NCT00136786

Locations: 🇺🇸
New York State Psychiatric Institute, New York, New York, United States

The Effects of Memantine and Bupropion on Acute, Reinforcing, and Conditioned Effects of Cigarettes - 1

Phase 1

Completed

Conditions: Tobacco Use Disorder

Interventions: Drug: placebo
Drug: Memantine
Drug: bupropion

First Posted Date: 2005-08-29

Last Posted Date: 2018-05-21

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 45

Registration Number: NCT00136747

Locations: 🇺🇸
New York State Psychiatric Institute, New York, New York, United States

Effectiveness of Memantine in Treating Cocaine-Dependent Individuals - 2

Phase 2

Completed

Conditions: Cocaine-Related Disorders

Interventions: Drug: placebo
Drug: Memantine

First Posted Date: 2005-08-25

Last Posted Date: 2019-04-24

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 81

Registration Number: NCT00134901

Locations: 🇺🇸
Research Foundation for Mental Hygiene, Inc., New York, New York, United States

Memantine and Naltrexone Treatment for Opioid Dependence

Phase 2

Completed

Conditions: Opioid Dependence

Interventions: Drug: Memantine
Drug: Naltrexone

First Posted Date: 2005-08-01

Last Posted Date: 2018-06-18

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 81

Registration Number: NCT00125515

Locations: 🇺🇸
New York State Psychiatric Institute, New York, New York, United States

Memantine and Comprehensive, Individualized Management of Alzheimer's Disease and Caregiver Training

Phase 4

Completed

Conditions: Alzheimer's Disease

Interventions: Behavioral: Individualized management of AD including caregiver training
Drug: Memantine

First Posted Date: 2005-07-19

Last Posted Date: 2016-10-25

Lead Sponsor: NYU Langone Health

Target Recruit Count: 20

Registration Number: NCT00120874

Locations: 🇺🇸
Fisher Alzheimer's Program, New York University School of Medicine, New York, New York, United States

An Evaluation of the Safety and Efficacy of Memantine in Patients With Acute Mania Associated With Bipolar I Disorder

Phase 2

Completed

Conditions: Bipolar Disorder

First Posted Date: 2005-03-25

Last Posted Date: 2012-03-05

Lead Sponsor: Forest Laboratories

Target Recruit Count: 35

Registration Number: NCT00106405

Locations: 🇺🇸
St. Charles Psychiatric Associates, St. Charles, Missouri, United States
🇺🇸
Sheppard Pratt Health System, Baltimore, Maryland, United States
🇺🇸
Synergy Clinical Research Center, National City, California, United States

and more 3 locations

An Evaluation of the Safety and Efficacy of Memantine in Agitated Patients With Moderate to Severe Alzheimer's Disease

Phase 3

Completed

Conditions: Alzheimer's Disease

First Posted Date: 2004-12-02

Last Posted Date: 2012-03-05

Lead Sponsor: Forest Laboratories

Target Recruit Count: 34

Registration Number: NCT00097916

Locations: 🇺🇸
The Forves Norris MDA/ALS Research Center, San Francisco, California, United States
🇺🇸
Coastal Communities Hospital, Westminster, California, United States
🇺🇸
Berma Research Group, Hialeah, Florida, United States

and more 6 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy